Literature DB >> 23147254

The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.

O Abdel-Wahab1, A Dey.   

Abstract

The recent identification of germline and somatic mutations in BAP1 as well as in multiple members of the ASXL (additional sex combs-like) family of genes has highlighted the role of these proteins in a diverse array of biological functions. A diverse number of possible functions have previously been ascribed to ASXL1 in non-hematopoietic contexts, including physical co-operativity with HP1a and LSD1. Here we discuss new evidence for a BAP1-independent function of ASXL1 in regulating histone H3 lysine 27 methylation through interactions with the Polycomb-repressive complex 2 (PRC2). BAP1, a nuclear-localized deubiquitinase, has been shown to interact with a number of proteins, including ASXL1 and/or ASXL2, but the functional importance of this interaction has remained elusive. Here, we highlight recent work revealing the critical function of BAP1 in restricting myelopoiesis and in regulating hematopoietic stem cell function. These data provide evidence that BAP1 and ASXL1 function as a novel class of tumor suppressors in myeloid malignancies. BAP1 functions through effects on stability of host cell factor-1, and O-GlcNAcylation, and ASXL1 impacts histone post-translational modifications through interaction with PRC2. Future studies investigating the mechanism of transformation by loss of BAP1 and ASXL1 may result in new therapeutic approaches to treat hematological malignancies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23147254     DOI: 10.1038/leu.2012.288

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  37 in total

Review 1.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

Review 2.  Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?

Authors:  Maximilian Stahl; Benjamin Y Lu; Tae Kon Kim; Amer M Zeidan
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

Review 3.  Epigenetic regulators and their impact on therapy in acute myeloid leukemia.

Authors:  Friederike Pastore; Ross L Levine
Journal:  Haematologica       Date:  2016-03       Impact factor: 9.941

Review 4.  Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.

Authors:  Guillermo Montalbán Bravo; Elinor Lee; Bryan Merchan; Hagop M Kantarjian; Guillermo García-Manero
Journal:  Br J Haematol       Date:  2014-06-05       Impact factor: 6.998

Review 5.  O-GlcNAc signaling in cancer metabolism and epigenetics.

Authors:  Jay Prakash Singh; Kaisi Zhang; Jing Wu; Xiaoyong Yang
Journal:  Cancer Lett       Date:  2014-04-24       Impact factor: 8.679

6.  ASXL1 impairs osteoclast formation by epigenetic regulation of NFATc1.

Authors:  Nidhi Rohatgi; Wei Zou; Patrick L Collins; Jonathan R Brestoff; Timothy H Chen; Yousef Abu-Amer; Steven L Teitelbaum
Journal:  Blood Adv       Date:  2018-10-09

Review 7.  Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research.

Authors:  Ting Zhou; Marsha C Kinney; Linda M Scott; Sandra S Zinkel; Vivienne I Rebel
Journal:  Blood       Date:  2015-06-15       Impact factor: 22.113

8.  Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation.

Authors:  Robert R West; Amy P Hsu; Steven M Holland; Jennifer Cuellar-Rodriguez; Dennis D Hickstein
Journal:  Haematologica       Date:  2013-09-27       Impact factor: 9.941

Review 9.  Maintaining cell identity: PRC2-mediated regulation of transcription and cancer.

Authors:  Itys Comet; Eva M Riising; Benjamin Leblanc; Kristian Helin
Journal:  Nat Rev Cancer       Date:  2016-09-23       Impact factor: 60.716

10.  Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria.

Authors:  Wenyi Shen; Michael J Clemente; Naoko Hosono; Kenichi Yoshida; Bartlomiej Przychodzen; Tetsuichi Yoshizato; Yuichi Shiraishi; Satoru Miyano; Seishi Ogawa; Jaroslaw P Maciejewski; Hideki Makishima
Journal:  J Clin Invest       Date:  2014-09-17       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.